Novel players in cardioprotection: Insulin like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9)
Author
dc.contributor.author
Westermeier, Francisco
Author
dc.contributor.author
Bustamante, Mario
Author
dc.contributor.author
Pavez, Mario
Author
dc.contributor.author
García Nannig, Lorena
Author
dc.contributor.author
Chiong Lay, Mario
Author
dc.contributor.author
Ocaranza, María Paz
Author
dc.contributor.author
Lavandero González, Sergio
Admission date
dc.date.accessioned
2015-12-29T20:11:00Z
Available date
dc.date.available
2015-12-29T20:11:00Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
Pharmacological Research 101 (2015) 41–55
en_US
Identifier
dc.identifier.other
DOI: 10.1016/j.phrs.2015.06.018
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/136047
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Insulin-like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9) have been proposed to be important mediators in cardioprotection. A large body of evidence indicates that insulin like growth factor-1 has pleotropic actions in the heart (i.e., contractility, metabolism, hypertrophy, autophagy, senescence and cell death) and, conversely, its deficiency is associated with impaired cardiac function. Recently, we reported that insulin like growth factor-1 receptor is also located in plasma membrane invaginations with perinuclear localization, highlighting the role of nuclear Ca2+ signaling in the heart. In parallel, angiotensin-(1-7) and angiotensin (1-9) acting through Mas receptor and angiotensin type 2 receptor have emerged as a novel anti-hypertensive molecules promoting vasodilatation and preventing heart hypertrophy. In this review we discuss the scientific evidence available regarding insulin-like growth factor-1, angiotensin-(1-7) and angiotensin-(1-9) in cardioprotection and its potential application as novel therapeutic targets for treating cardiac diseases. (c) 2015 Elsevier Ltd. All rights reserved.
en_US
Patrocinador
dc.description.sponsorship
Comision Nacional de Ciencia y Tecnologia (CONICYT), Chile; FONDEF; Anillo; FONDECYT; CONICYT
The aim of this study was to estimate the prevalence of the different alleles of the angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and associated plasma ACE activity, as well as cardiac ...
In patients with hypertension who have the DD-ACE genotype (higher angiotensin-converting enzyme [ACE] activity), plasma levels of angiotensin-(1-7) are 4 times lower than in patients with the II-ACE genotype (lower ACE ...
Aránguiz Urroz, Pablo Daniel; Soto Muñoz, Dagoberto; Contreras Ferrat, Ariel Eduardo; Troncoso Cotal, Rodrigo; Chiong Lay, Mario; Montenegro Obregón, José Joaquín; Venegas Pino, Daniel Esteban; Smolic Smolic, Christian; Ayala Jeria, Pedro Segundo; Thomas, W. G.; Lavandero González, Sergio; Díaz Araya, Guillermo(NATURE PUBLISHING GROUP, 2009-05)
The Angiotensin II (Ang II) type 1 (AT(1)R) and type 2 (AT(2)R) receptors are increased in the heart following myocardial infarction and dilated cardiomyopathy, yet their contribution at a cellular level to compensation ...